Eli Lilly’s Mounjaro Shows Promising Results in Children with Type 2 Diabetes
CompanyDrug

Eli Lilly’s Mounjaro Shows Promising Results in Children with Type 2 Diabetes

Siemens Healthineers and Stryker Forge Neurovascular Robotics Alliance
CompanyDeals

Siemens Healthineers and Stryker Forge Neurovascular Robotics Alliance

China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs
DrugPolicy / Regulatory

China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs

Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1 B in Cardio siRNA Deal
CompanyDeals

Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1 B in Cardio siRNA Deal

Cook Medical & Siemens Healthineers Partner to Launch First Radiation‑Free iMRI Suite
CompanyDeals

Cook Medical & Siemens Healthineers Partner to Launch First Radiation‑Free iMRI Suite

Eli Lilly Unveils $5 B Virginia Facility to Scale Bioconjugate & Antibody Production
Company

Eli Lilly Unveils $5 B Virginia Facility to Scale Bioconjugate & Antibody Production

AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy
Company

AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD
CompanyDrug

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD

Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424
CompanyDeals

Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424

Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices
Policy / Regulatory

Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices

GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities
Company

GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities

Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound
CompanyDrug

Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound